Running Parallel with EuroTIDES - 2 Events, 1 Price EuroPEPTIDES

Transcription

1 Informa Life Sciences 4th Annual Running Parallel with EuroTIDES - 2 Events, 1 Price EuroPEPTIDES The global peptide therapeutics market set to to reach $25.5 billion by Don t miss out on your share of this potential revenue Wednesday 13th to Thursday 14th November 2013 Clarion Congress Hotel Prague, Czech Republic Europe s leading industy- driven peptide event, focusing on ground-breaking advances across research, development, clinical, manufacturing and delivery 25+ Speakers 16+ Hours of New Science 2 Interactive Workshops 9+ Hours of Networking 3 Tracked - Co-located with EuroTIDES Konrad Bleicher, Vice Director, pred Basel, Discovery Chemistry, F. Hoffmann-La Roche, Switzerland Ditte Riber, Head of Peptide Design, Zealand Pharma, Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk, Ho Sung Cho, Chief Technology Officer, Ambrx, Inc., USA Joël Richard, Vice President Peptides CMC & Engineering, IPSEN, France Judit Tulla-Puche, Research Associate, Institute for Research in Biomedicine (IRB Barcelona), Spain New for industry case studies on cutting edge peptide developments including strategic insights from F.Hoffmann-La Roche, Novo Nordisk, Zealand Pharma, Ispen and GlaxoSmithKline NEW interactive strategic roundtable discussions on choosing effective peptide manufacturing methods and evaluating alternative approaches to PEGylation for extending the half-life and stability of peptide products Two NEW workshops on the development of peptide conjugated therapeutics and strategies for successful peptide development and manufacturing NEW session on peptides diagnostics and biomarkers with talks from Roche Diagnostics and University of Florence Key Reasons to Attend Europe s Leading Industy-Driven Peptide Event Benchmark your pre-clinical and clinical programmes with 6 case studies from leading peptide companies: F.Hoffmann-La Roche, Zealand Pharma, Radius, GlaxoSmithKline, Ferring Pharmaceuticals and Amunix Operating Inc. Discover winning formulation strategies and the most successful technologies for sustained release of your peptide product Uncover cutting edge developments in non-invasive delivery methods including recent developments in oral and intra-/transdermal peptide delivery Evaluate new techniques to improve solid phase peptide synthesis and optimise large scale peptide manufacturing Explore advances in analytical technologies for the physico-chemical and structural characterisation of novel peptides and conjugates including the application of high resolution MS Choice of 2 Brand New Workshops Register online: Speakers at the Forefront of Peptide Development Including: 4 Laurent Jespers, VP Innovation Biopharm Discovery Unit, Head Biopharm R&D, GlaxoSmithKline, UK 4 Tom Loughman, Director of API Development, Ipsen, Ireland 4 Lars Grundemar, Associate Vice President, Ferring Pharmaceuticals, 4 Gary Hattersley, Senior Vice President, Preclinical Development, Radius, USA 4 Douglas A. Treco, President and CEO, Ra Pharmaceuticals, Inc. USA 4 Rob Livingston, Head of Process Development, Pharmaceutical Development, Ironwood Pharmaceuticals, USA 4 Alistair Kippen, Director, Analytical Biochemistry R&D, MedImmune, UK PRE CONFERENCE WORKSHOPS Tuesday 12 November 2013 Design and Development Strategies for Peptide Conjugated Therapeutics Workshop Leader: Ho Sung Cho, Chief Technology Officer, Ambrx, Inc., USA 4 Anna Maria Papini, Professor of Bioorganic Chemistry, Chaire d Excellence of the Agence Nationale de la Recherche, French-Italian Laboratory of Peptide & Protein Chemistry & Biology, University of Florence (Italy) and University of Cergy-Pontoise (France) POST CONFERENCE WORKSHOP Friday 15 November 2013 Strategies for Successful Peptide Development and Manufacturing Workshop Leader: Vincent Bille, Managing Director, Marble Pharma Consult, Belgium EVENT SPONSORS Brand NEW workshops on Peptide conjugated therapeutics and successful peptide development and manufacturing Scan with smartphone QR Reader App:

2 DAY ONE: WEDNESDAY 13 NOVEMBER :00 Registration and Morning Coffee 09:00 Chairperson s Opening Remarks and Welcome Address Innovations and Opportunities in Peptide Development KEYNOTE PRESENTATION Optimising the Therapeutic Performance of Peptides through Bio- Conjugation The physio-chemical properties of many peptides pose significant challenges for development and realising commercial success. Ambrx is performing protein medicinal chemistry with an expanded genetic code to create bio-conjugates to improve the in vivo performance of peptides- optimising PK, PD as well as their drug like properties. The benefits of site-specific conjugation for enabling development and manufacturing of peptide-bio conjugates, as well as future trends, including the targeted, extra-cellular and intra-cellular delivery will be discussed. Ho Sung Cho, Chief Technology Officer, Ambrx, Inc., USA Trends in Peptide Process Development Peptide manufacturing process development is currently undergoing significant changes. The increasing variation in peptide structural motifs; the strategic decisions to be made between the choice of classical solution phase versus the solid phase chemistries or a combined hybrid approach, the pressures on cost and time throughout the development and the introduction of Quality by Design principles are all factors that drive change. This presentation will highlight some of the most prominent trends, consequences and opportunities. Jon Holbech Rasmussen, Global Director of Development, PolyPeptide Group, Sweden 10:15 Morning Coffee in the Exhibition Hall/Poster Hall Opens Cutting Edge Peptide Therapeutics in Preclinical and Clinical Development 10:40 From GLP-1 to Glucagon: The Next Generation Diabesity Treatment? GLP-1, an incretin hormone excreted from gastrointestinal L-cells, regulates glucose levels through its pancreatic insulin secretagogue activity. In addition, it reduces food intake via delay of gastric emptying and central satiety signalling. Accordingly, new drugs have been developed that either mimic the action of GLP-1 or reduce its enzymatic degradation (DPPIV inhibitors). Glucagon, the counter-regulatory hormone of insulin, increases glucose levels through the stimulation of glycogenolysis and gluconeogenesis but also positively impacts metabolic factors such as energy expenditure, lipolysis, fatty acid oxidation etc. This lecture will cover our efforts to generate clinical leads with combined incretin as well as glucagon pharmacology. Konrad Bleicher, Vice Director, pred Basel, Discovery Chemistry, F. Hoffmann-La Roche, Switzerland 11:10 Turning Peptides into Drugs: A Preclinical Perspective For more information on this talk please refer to the event website com/peptides Ditte Riber, Head of Peptide Design, Zealand Pharma, 11:40 Development of a Novel Bone Anabolic Peptide Analog of hpthrp for the Treatment of Osteoporosis Osteoporosis is a disease characterised by decreased bone mass and quality, leading to a high risk of fractures. Osteoporotic fractures are associated with high morbidity, mortality and represent a major economic burden. There is a significant need for new therapeutic agents that can reverse bone loss. BA058 is a novel peptide analog of hpthrp with potent bone anabolic properties demonstrated in preclinical models and in a completed Phase 2 clinical study. In addition to a subcutaneous injection form of BA058, a short wear time transdermal patch is also being developed with the potential to improve patient convenience. Gary Hattersley, Senior Vice President, Preclinical Development, Radius, USA 12:10 Cutting Edge Peptide Therapeutics- Insights from GSK For more information on this talk please refer to the event website Laurent Jespers, VP Innovation Biopharm Discovery Unit, Head Biopharm R&D, GlaxoSmithKline, UK 12:40 Lunch and Poster/ Exhibition Viewing Time 14:00 Development of Peptide -Drug Conjugates for Oncology Based on XTEN, a Protein-Based Polymer with Precisely Controlled Chemical Composition Amunix has developed XTEN, a protein-based polymer that mimics the biophysical properties of PEG, to extend the serum half-lives of attached therapeutics. Multiple conjugation sites can be introduced into XTEN in precisely controlled locations. XTEN is monodisperse, which greatly facilitates the purification of multivalent conjugates. The precisely controlled structure and hydrophilicity of XTEN enables product characterisation via HPLC and MS. XTEN-drug conjugates have very low systemic toxicity as XTEN prevents non-specific tissue uptake of drug moieties. The conjugation of peptides or other moieties confers tumor-selective uptake to XTENdrug molecules. Currently, XTEN-peptide fusions and conjugates are in various stages of preclinical and clinical development. Resulting data confirm the nonimmunogenic nature of XTEN as well as its ability to confer class-leading time action in vivo. The biodegradable nature of XTEN eliminates the risk of bioaccumulation that can be observed for PEGylated molecules. Volker Schellenberger, President and CEO, Amunix Operating Inc. USA 14:30 Update on Peptide Therapeutics in Clinical Development For more information on this talk please refer to the event website com/peptides Lars Grundemar, Associate Vice President, Ferring Pharmaceuticals, Advances in Analytical Technologies and Purification Methodology 15:00 Application of High Resolution MS for the Analysis and Characterisation of Peptide APIs Cases studies detailing how Ipsen utilises high resolution mass spectrometry in the development of novel peptide APIs as well as for regulatory support in life cycle management of commercial peptide APIs. The focus shall be on the need to identify critical target intermediates in the development of peptide NCEs, the manufacture of which can involve ligation technologies which include the attachment of small molecules or PEG groups. A discussion on the utility of MS in confirming the removal of solid phase coupling reagents will also be presented. Finally a brief case study on impurity identification in life cycle management activities will be presented. Tom Loughman, Director of API Development, Ipsen, Ireland 15:30 A New MAS-NMR Method for Quality Control of Solid Supports for SPPS A newly developed HR-MAS-NMR method as a fast and reliable analytical tool for the quantification of remaining benzyl alcohol moieties in Fmoc-Xaa-Wang resins is presented. Compared to established test synthesis protocols, this method represents not only advantages in terms of time and cost savings, but also eliminates all inaccuracies due to further sample treatment like SPPS and resin cleavage. Markus Wiesner, Biochemicals & Process Research, Bachem AG, Switzerland 16:00 Afternoon Coffee in the Exhibition Hall with Poster Viewing Time 16:30 Structural Characterisation of Novel Peptide Therapeutics Presentation on the advances of analytics for physico-chemical and structural characterisation of novel peptides and conjugates. Feedback on techniques such as UPLC, high resolution MS, LC-MS, DSC to evaluate chemical/structural changes, impurities, degradation and QC for optimisation of formulation and stability will be discussed. Alistair Kippen, Director, Analytical Biochemistry R&D, MedImmune, UK Latest Developments in Non-Invasive Delivery Methods 17:00 Present Status and Future Developments in Non-Invasive, Sustained Released Alternative Delivery Methods for Peptides Peptide drugs which are mainly parenterals, are used in an increasing number of various therapeutic areas, including type 2 diabetes, obesity, metabolic syndromes, and oncology. The recent progresses in the field of peptide delivery will be reviewed, focusing on the most successful technologies for sustained release (SR) over very long periods of time (3 to 12 months), the new emerging paradigms of solvent-free, water-based, ready-to-use peptide formulations and devices, spontaneous selfassociation of peptides dictated by non-covalent interactions, as well as the longerterm perspectives for alternative, non-invasive routes of administration, like oral and intra-/trans-dermal peptide delivery. Joël Richard, Vice President, Peptides, CMC and Engineering, Ipsen, France 17:30 The Unseen Advantages of Per-Oral Protein Therapeutics Oral peptides are attractive because they bypass injection, but other benefits are gained, because materials crossing the gut pass straight into the liver. This is particularly appropriate for insulin, where the liver is the prime organ controlling glucose metabolism. Also, oral insulin avoids entering the peripheral circulation, where it can cause serious side effects. Similar benefits may arise through oral administration of other proteins, such as GLP-1 and PTH. A novel approach to oral administration of labile peptides is presented. Roger New, Co-Founder & CSO, Diabetology Ltd, UK 18:00 Industry Case Study: Advances in Oral Peptide Drug Delivery Products For more information on this talk please refer to the event website Douglas A. Treco, President and CEO, Ra Pharmaceuticals, Inc. USA 18:30 Chairperson s Closing Remarks 18:35 Drinks Reception in the Exhibition Hall with EuroTIDES delegates followed by an Optional Dinner (See page 4 for more details)

3 08:30 Chairperson s Opening Remarks and Welcome Address Process Optimisation and Large Scale API and Industrial Synthesis 08:35 Recent Advances in Solid-Phase Peptide Synthesis Techniques Complex peptides such as long, cyclic, hydrophobic or N-methylated peptides require highly optimised strategies to overcome aggregation, difficult couplings or side-reactions. A special case involves also depsipeptides, which bear the delicate ester bond. Therefore, the choice of solid support, protecting groups, and coupling reagents, which will be the cornerstone of the presentation, becomes crucial in reaching the target compound in good yields and purities. Judit Tulla-Puche, Research Associate, Institute for Research in Biomedicine (IRB Barcelona), Spain 09:05 Economic Continuous Reversed Phase Mode Chromatography As the biopharmaceutical industry evolves, the need for advanced biomanufacturing becomes critical, especially for downstream solutions where increased productivity and improved economics without sacrificing process robustness should be offered. In this presentation, we explore the advantages of continuous chromatography through reversed phase chromatography. In major tested applications, experimental data confirm significant increase in productivity as well as reduced buffer consumption and enhanced resin utilisation without impacting critical product quality attributes. In combination, these features enable continuous chromatography to be easily adapted to standard purification templates, but also potentially make disposable chromatography a reality. Romas Skudas, Senior Scientist, Process Purification Downstream Technologies, Merck Millipore, Germany 09:35 Chemical Development of Disulfide Rich Peptides The robust metabolic stability of linaclotide is largely attributable to its dense network of disulfide bonds (three disulfide bonds contained within 14 amino acids). This same structural feature presents additional considerations with respect to synthesis, analysis, and stability. General strategies and techniques for characterising and developing peptides containing multiple disulfide bonds will be discussed Rob Livingston, Head of Process Development, Pharmaceutical Development, Ironwood Pharmaceuticals, USA 10:05 The Use of Fmoc-Pseudoproline Dipeptides in the Synthesis of Large Peptides A fragment hybrid solution/solid phase synthesis of Exendin-4 utilising FMOC chemistry will be described. The positive impact of pseudoprolines on the fragment quality and yield is presented. Besides, the benefits of the precipitation of Exendin-4 at large scale (i.e. advantages of precipitation vs lyophilization) are discussed. Thomas Nsenda, Associate Director, Commercial Development, CordenPharma, Switzerland 10:35 Morning Coffee in the Exhibition Hall 11:05 INTERACTIVE ROUNDTABLE DISCUSSION Choosing Effective Peptide Manufacturing Methods for your Product Chemical vs. biological production Evaluation of industrial synthesis strategies: Liquid vs. solid phase vs. recombinant vs. hybrid approaches Pros and cons of methods Types of products methods applicable for and when to choose each method Evaluating applicability for method for use with long peptide chains and conjugated peptides Adding chemical modifications to peptide chains Cost analysis of different methods Regulatory acceptance Discussion Leaders Include: Jon Holbech Rasmussen, Global Director of Development, PolyPeptide Group, Sweden Formulation Strategies for Sustained Release 11:45 Formulation Strategies for the Sustained Release of Peptide Drugs Sustained release systems have typically focused on optimising marketed compounds, improving their effectiveness or tolerability, and simplifying their administration. As drugdelivery technologies come into play earlier in the development cycle, they can also boost the screening and evaluation of new compounds. This talk outlines the main aspects of early stage development for peptides sustained release technologies and provides an insight for development approaches. Ana Dos Santos, Senior Scientist, Medimmune, UK 12:15 Spotlight Presentation This presentation will be hosted by a leading company who operates in the field of peptides. Please contact: [email protected] +44 (0) :45 Lunch and Poster/ Exhibition Viewing Time Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk, Jesse Dong, VP Compound Discovery, Ipsen, USA Matthias Urmann, R&D DIAB Division / Insulin & Peptides, Sanofi-Aventis Deutschland GmbH, Germany Neil Thompson, Associate Director, PolyPeptide Group, UK Bruce Morimoto, VP Drug Development, Celerion, USA DAY TWO: THURSDAY 14 NOVEMBER 2013 With Special Thanks to the EuroPEPTIDES Advisory Board: 14:00 Peptide Formulation Strategies for the Sustained Release of Peptide Drugs Naked peptides in aqueous solution rarely provide sustained release features making formulation technologies essential for the addition of such properties to the target product profile. Formulation design strategies to enable development of peptide sustained release products will be presented with a focus on parenteral formulation technologies. Long-acting formulation technologies may also effectively be used for life-cycle management in terms of improved efficacy and patient convenience as well as targeting of new indications and patient populations. Markus Johnsson, Senior Director, Pharmaceutical Development, Camurus AB, Sweden Strategies for Increasing the Half Life and Stability of Peptide Products 14:30 Pharmaceutical Protein and Peptide Engineering The development of biotechnology has given access to novel peptides and proteins (NBEs) for treatment of various diseases. However, clinical trials of NBEs have frequently resulted in limited success due to low efficacy or low duration of action due to inappropriate properties such as lack of enzymatic stability or high systemic clearance. Another general challenge is drug product stability due to low chemical or physical stability or low aqueous solubility. During the last decade various protein engineering technologies has developed significantly to optimise the properties of NBEs to stable and efficacious drugs with improved pharmaceutical profiles. The in vivo parameters that often are being optimised includes renal clearance (by adding mass and charge to the protein), liver elimination (by removal or hiding of specific receptor signatures), and plasma elimination (by elimination of proteolytic sites with amino acid substitutions). In addition the biophysical properties addressing stability of drug product is often being optimised to obtain a successful drug candidate. The presentation will discuss these matters and exemplify how the interface of organic chemistry and protein chemistry can generate solutions to improve the pharmaceutical properties of peptides and proteins using case stories from glucagon like peptide 1 and insulin. Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk, 15:00 Afternoon Coffee in the Exhibition Hall with Poster Viewing Time Volker Schellenberger, President and CEO, Amunix Operating Inc. USA Sönke Stocker, Business Development Manager, Bachem AG, Switzerland Bernd Raschack, Bachem AG, Switzerland Anna Maria Papini, Professor of Bioorganic Chemistry, Chaire d Excellence of the Agence Nationale de la Recherche, French-Italian Laboratory of Peptide & Protein Chemistry & Biology. University of Florence (Italy) and University of Cergy-Pontoise (France) 15:30 STRATEGIC DISCUSSION SESSION Evaluating Alternative Approaches to PEGylation for Extending the Half Life and Stability of Peptide Products Each speaker will present a short 15 minute overview to outline their novel method to improve the half-life and retention rates of peptide products and its application to peptide drug products. This session will be followed by a dedicated discussion session with the audience. Topics to be discussed include: Comparison of alternative approaches to PEGylation for extending the half-life and maintaining the in vivo potency of peptides Technologies to chemically modify peptides: PAS, HES, XTEN, Fusion Protein How do approaches impact bio distribution and half-life? Overcoming stability issues for peptides Preclinical developments: Are novel half-life extension techniques scaling the same way as PEGylated products? Clinical validation of half-life extension alternatives to PEG Case study on application and development on use of approach in peptide therapeutics Discussion Leaders Include: Joël Richard, Vice President Peptides CMC & Engineering, IPSEN, France Arne Skerra, Managing Director, Co-Founder, XL-protein GmbH, Germany Volker Schellenberger, President and CEO, Amunix Operating Inc. USA Peptide Diagnostics and Biomarkers 16:30 New Frontiers in the Development of Peptides for Diagnostic Applications Personalised Healthcare (PHC) will provide a more systematic and effective approach to modern medical care. To deliver this new paradigm, a crucial role will be played by specifically designed diagnostic assays. To achieve the performance that is necessary for this role will require both tailored assays and also unique reagent solutions. In this presentation selected case studies for the design and synthesis of novel peptide tools for the development of companion diagnostic (cdx) assays will be discussed. Sebastian Dziadek, Development Leader R&D, PHC Assays Development, Roche Diagnostics, Germany 17:00 Optimised Synthetic Strategies to Post-Translationally Modfied Peptides as Reliable Diagnostics of Immune-Mediated Diseases Biomarkers are decision-making tools at the basis of clinical diagnostics essential for guiding therapeutic treatments. In this context, autoimmune diseases represent a class of disorders that need early diagnosis and steady monitoring. Post-translational modified peptides are the best candidate mimicking linear and conformational epitopes to fishing out autoantibodies as disease biomarkers. Introduction of specific PTMs by optimised and innovative solid-phase peptide synthesis can lead to univocally characterised molecules, which can be indefinitely reproduced to develop the most reliable immunoassays. Anna Maria Papini, Professor of Bioorganic Chemistry, Chaire d Excellence of the Agence Nationale de la Recherche, French-Italian Laboratory of Peptide & Protein Chemistry & Biology, University of Florence (Italy) and University of Cergy-Pontoise (France) 17:30 Chairperson s Closing Remarks and End of Conference

4 DON T FORGET TO RESERVE YOUR PLACE AT ONE OF OUR 2 NEW INTERACTIVE WORKSHOPS PRE-CONFERENCE WORKSHOP: TUESDAY 12 NOVEMBER 2013 Design and Development Strategies for Peptide Conjugated Therapeutics Registration 09:30 Start 10:00 End no later than 16:00 Morning, afternoon and lunch breaks are included A This full day interactive workshop will focus on practical R&D strategies for peptide-conjugated therapeutics. Through a series of case study examples and interactive discussions the workshop will explore the latest techniques for designing, developing, scale up and manufacturing, analysis and delivery systems for conjugated peptide products. Topics to be addressed include: Design of peptide conjugated therapeutics Novel modification methods and technologies to introduce conjugations Techniques to control peptide structure and properties when conjugated to larger protein molecules Clinical Developments Peptide-antibody conjugates in phase I, II or III development Analysis and Characterisation Identifying and characterising the peptide molecule in conjugations to large molecules Drug Delivery and Formulation Strategies Extending the half-life: How to hold the efficiency of peptide in conjugation Scale Up and Manufacturing Strategies Synthetic manufacturing with multiple attachments: How large can you go? Introducing modifications for complex conjugations: One pot synthesis or are attachments added later? Which methods are approved by regulatory authorities for the use for conjugated peptides? Workshop Chairman: Ho Sung Cho, Chief Technology Officer, Ambrx, Inc., USA Please visit the event website for further details on workshop presentations and leaders POST CONFERENCE WORKSHOP: FRIDAY 15 NOVEMBER 2013 Strategies for Successful Peptide Development and Manufacturing Registration 08:30 Start 09:00 End no later than 15:00 Morning, afternoon and lunch breaks are included X This interactive workshop will provide delegates with an opportunity to discuss the latest strategies for optimising the manufacture of peptide therapeutics. As contract organisations are a major part of most development efforts, it is becoming increasingly important to consider business issues such as intellectual property, know how, confidentiality, mutual expectations and constraints and other factors when choosing a manufacturing partner. This workshop will include case studies for managing the technical and business aspects of process and analytical development for commercial and regulatory success in order to invite all attendees to share their experiences and discuss best practices in the area Topics to be addressed include: Strategies for management of manufacturing and quality control during early stage development Process development and manufacturing management Methods for successful scale up How can you reduce costs in the scale up process Strategies for manufacturing success: Managing intellectual property and know-how challenges Considerations for peptide contract manufacturing: Lessons learnt on outsource management CMO-sponsor collaboration: Aligning the manufacturing approach with the drug development stage; Aligning both sides expectations Tech transfer in peptide manufacturing Analytics and quantification Process validation and meeting regulatory requirements Workshop Leader: Vincent Bille, Managing Director, Marble Pharma Consult, Belgium Networking Dinner - Wednesday 13 November Help us celebrate the event by joining us for our popular dinner reception which will be held in the evening of Day One. This is an ideal time to meet with business leaders from many of the most notable companies operating in the peptide industry today. Catch up with old colleagues, make new contacts and take time to mingle with the speakers, all against the beautiful background of Prague. At Mlýnec, Prague s top restaurant, you will enjoy a unique drama at your table written by Marek Purkart, the first Czech chef to receive the Michelin Bib Gourmand award three times. Superbly situated at the foot of the famous Charles Bridge, Mlýnec s interior and terrace offer a spectacular view of the Charles Bridge. Limited places are available so book early - Cost is included in the conference fee (not applicable if booked via a sponsor or exhibitor contract). Transport to and from the Congress Hotel will be provided. Sold out in 2012 so please book early. SOLD OUT IN 2012, SO BOOK EARLY MEDIA PARTNERS

5 EVERYTHING YOU NEED TO KNOW ABOUT THE EVENT 2012 Attendee Breakdown Geographical Split Job Title Split Europe - 74% Vice President - 57% CEO/CSO/CFO - 15% Middle East - 2% Director/Manager - 5% Asia - 6% Scientist - 20% USA - 14% Regulatory Affairs - 3% To apply for exhibition / sponsorship opportunities please contact: [email protected] or +44(0) % EVENT GROWTH (2011 vs 2012) Attendee Conference Rating Attendee Content Rating Russia - 4% Last year s meeting was very high quality and resulted in a new collaboration for our company Volker Schellenberger, President and CEO, Amunix Operating Inc, USA Interesting program, nice atmosphere Rekdal, Lytix Biopharma Attendee Networking Rating Sold out exhibition in WAYS TO MEET PEOPLE - Utilise our networking activities and improve your conference experience NEW: TIDES CONNECT SPEED PARTNERING MOBILE APP NETWORKING DINNER EXHIBITION HALL DRINKS RECEPTION How to Submit a Poster Application: In recognition of the significant educational impact and value poster presentations provide our attendees, the organisers at EuroPEPTIDES have created the 2013 EuroPEPTIDES Best Poster Award. To apply, please send your abstract of 200 words or fewer, written in English, listing the principle author and all contact details to catherine.marshall@ informa.com Last date for submission is Friday 25th October 2013 Posters submitted by academics, biopharmaceutical and pharmaceutical organisations will not be charged a fee Posters submitted by service providers/vendors are welcome and will be subject to evaluation by the scientific advisory board. Upon approval a fee of VAT will apply Posters will be 1m x 1.5m portrait and held in the exhibition New for TIDES Connect TIDES Connect is a networking facility available to all attendees enabling you to make contacts and plan meetings. With a user friendly website open pre-event and a mobile app version for you to take onsite, TIDES Connect will answer all your partnering needs Sponsors & Exhibitors at time of print To apply for exhibition / sponsorship opportunities please contact: [email protected] or +44(0) Exhibition Summary Limited Booth space only 8 x booths remain available 4 x available speaking slots Over 11 x hours of networking available For more information about exhibition & sponsorship contact: [email protected] +44 (0)